Patents by Inventor John Burnier

John Burnier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20230331711
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Application
    Filed: June 20, 2023
    Publication date: October 19, 2023
    Inventors: John BURNIER, Thomas GADEK, Frederic NAUD
  • COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20230233551
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: July 27, 2022
    Publication date: July 27, 2023
    Inventors: Thomas GADEK, John BURNIER
  • CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20220073500
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Application
    Filed: May 18, 2021
    Publication date: March 10, 2022
    Applicant: NOVARTIS PHARMACEUTICALS CORPORATION
    Inventors: John BURNIER, Thomas GADEK, Frederic NAUD
  • COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY
    Publication number: 20210338839
    Abstract: The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.
    Type: Application
    Filed: February 22, 2021
    Publication date: November 4, 2021
    Inventors: John BURNIER, Thomas GADEK, Charles SEMBA
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent number: 11028077
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: June 8, 2021
    Assignee: NOVARTIS PHARMACEUTICALS CORPORATION
    Inventors: John Burnier, Thomas Gadek, Frederic Naud
  • Compositions and methods for treatment of diabetic retinopathy
    Patent number: 10960087
    Abstract: The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: March 30, 2021
    Assignee: NOVARTIS AG
    Inventors: John Burnier, Thomas Gadek, Charles Semba
  • CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20200087287
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Application
    Filed: May 14, 2019
    Publication date: March 19, 2020
    Applicant: SARcode Bioscience Inc.
    Inventor: John BURNIER
  • Compositions and methods for treatment
    Patent number: 10188641
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: January 29, 2019
    Assignee: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20180251452
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Application
    Filed: January 29, 2018
    Publication date: September 6, 2018
    Applicant: SARcode Bioscience Inc.
    Inventor: John BURNIER
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent number: 9890141
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: February 13, 2018
    Assignee: SARCODE BIOSCIENCE INC.
    Inventor: John Burnier
  • COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20170143692
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: December 8, 2016
    Publication date: May 25, 2017
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas GADEK, John BURNIER
  • COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20170143691
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: November 30, 2016
    Publication date: May 25, 2017
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas GADEK, John BURNIER
  • COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20170143693
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: December 9, 2016
    Publication date: May 25, 2017
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas GADEK, John BURNIER
  • COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20170143690
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: November 21, 2016
    Publication date: May 25, 2017
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas GADEK, John BURNIER
  • CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20170029410
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Application
    Filed: May 3, 2016
    Publication date: February 2, 2017
    Applicant: SARcode Bioscience Inc.
    Inventor: John BURNIER
  • CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20160368902
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Application
    Filed: August 12, 2016
    Publication date: December 22, 2016
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: John BURNIER, Thomas GADEK, Frederic NAUD
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent number: 9447077
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: September 20, 2016
    Assignee: SARcode Bioscience Inc.
    Inventors: John Burnier, Thomas Gadek, Frederic Naud
  • COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY
    Publication number: 20160220702
    Abstract: The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.
    Type: Application
    Filed: March 17, 2015
    Publication date: August 4, 2016
    Applicant: Sarcode Bioscience Inc.
    Inventors: John BURNIER, Thomas Gadek, Charles Semba
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent number: 9353088
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: May 31, 2016
    Assignee: SARcode Bioscience Inc.
    Inventor: John Burnier
  • CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20150218135
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Application
    Filed: September 19, 2014
    Publication date: August 6, 2015
    Inventors: John BURNIER, Thomas GADEK, Frederic NAUD